Last update Jan. 30, 2022

سولفادوكسين

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Uultra-long-acting sulfonamide that is used in combination with Pyrimethamine as an antimalarial. Single-dose oral administration, a single dose for treatment and a weekly one for prophylaxis.

At the date of the last update, there was no published data available on its excretion in human milk.

No problems have been observed in infants whose mothers took it. (Kuemmerle 2020).

Use in infants is authorized from the second month (Saito 2018, Roche 2004), so it is unlikely that the amount that passes through the mother’s milk could affect the infant.

Various medical societies and expert consensus consider the use of this medication safe during lactation. (WHO 2010, Chattopadhyay 2007, Peters 2007)

WHO List of Essential Medicines 2002: compatible with lactation in healthy newborns, avoid, if possible, in premature infants and children under one month due to the risk of jaundice. Avoid in glucose-6-phosphate-dehydrogenase deficiency. (WHO-UNICEF 2002)


See below the information of this related product:

  • Pyrimethamine (Safe product and/or breastfeeding is the best option.)

Alternatives

  • Chloroquine (Safe product and/or breastfeeding is the best option.)
  • Mefloquine Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Quinine (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

سولفادوكسين is Sulfadoxine in Arabic.

Is written in other languages:

سولفادوكسين is also known as

Groups

سولفادوكسين belongs to these groups or families:

Tradenames

Main tradenames from several countries containing سولفادوكسين in its composition:

  • Fansidar™. Contains other elements than سولفادوكسين in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Alta - Hig %
Molecular weight 310 daltons
Protein Binding 90 %
VD 0.14 l/Kg
pKa 6.12 -
Tmax 4 hours
200 hours

References

  1. Kuemmerle A, Schmid C, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Ngolo D, Kisala M, Valverde Mordt O. Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2020 Jan 27;14(1):e0008028. Abstract Full text (link to original source)
  2. Saito M, Gilder ME, McGready R, Nosten F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018 Nov;17(11):1129-1144. Abstract Full text (link to original source) Full text (in our servers)
  3. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: WHO, 2010 2nd ed. Geneva: WHO, 2010 Full text (link to original source) Full text (in our servers)
  4. Chattopadhyay R, Mahajan B, Kumar S. Assessment of safety of the major antimalarial drugs. Expert Opin Drug Saf. 2007 Sep;6(5):505-21. Review. Abstract
  5. Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007;30(6):481-501. Review. Abstract
  6. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)

Total visits

1,050

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM